As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scalia asked CEO David Ricks if the company has taken the GLP-1 supply chain too far.
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’ Read More »
Bogle, Medtronic’s head of medical affairs for digital surgery, also discussed the company’s plans to train surgeons for its Hugo surgical robot.
Medtronic’s Orleigh Bogle on changing the culture of surgical training Read More »
With the $1.1 billion acquisition, Zimmer Biomet expects its sports medicine, extremities and trauma segment will outpace hips and knees.
Zimmer touts ASC opportunity with Paragon 28 purchase Read More »
Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the launch proceeding ahead of expectations.
BMS’ Cobenfy Sales Begin, With Launch Full Speed Ahead Read More »
Doctors groups signed on to lawsuits seeking to overturn policies that limit gender-affirming care for minors and remove some public-facing health information.
Providers sue Trump over gender-affirming care policies, purge of health information Read More »
Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of exclusivity for its blockbuster drugs Eliquis and Opdivo.
BMS Adds $2B to Cost Cutting Plans, Eyes Deals After Cobenfy Success Read More »
Generador de Imágenes en Bing La comunicación es la base de todo negocio que pretende convencer a un público de adquirir un producto o servicio. De hecho, no solo incide en la percepción que tienen los usuarios sobre tu empresa, sino que también …
The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last year received FDA approval to treat WHIM syndrome, in the larger patient population with chronic neutropenia.
X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce Read More »
Viracta’s closure comes on the heels of its delisting from Nasdaq last month and multiple rounds of layoffs last year.
Viracta Winds Down Business, Unable to Weather Financial Troubles Read More »
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” deal for the pharma.
AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations Read More »
